Bristol-Myers Squibb Co(BMY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | 13.54 | EPS (ttm) | 4.54 | Insider Own | 0.32% | Shs Outstand | 2.04B | Perf Week | 2.9% |
| Market Cap | 125.59B | Forward P/E | 9.29 | EPS next Y | 4.4% | Insider Trans | -0.1% | Shs Float | 2.04B | Perf Month | -0.03% |
| Enterprise Value | 159.57B | PEG | - | EPS next Q | 1.1 | Inst Own | 85.24% | Short Float | 2.25% | Perf Quarter | -1.73% |
| Income | 9.28B | P/S | 2.55 | EPS this Y | 3.03% | Inst Trans | 0.86% | Short Ratio | 3.9 | Perf Half Y | 4.72% |
| Sales | 49.20B | P/B | 5.63 | EPS next 5Y | -4.65% | ROA | 10.18% | Short Interest | 45.85M | Perf YTD | 13.98% |
| Book/sh | 10.92 | P/C | 11.35 | EPS past 3/5Y | 5.47% - | ROE | 46.7% | 52W High | -10.43% ($68.64) | Perf Year | 40.27% |
| Cash/sh | 5.42 | P/FCF | 10.98 | Sales past 3/5Y | 1.45% 2.54% | ROIC | 14.03% | 52W Low | 44.59% ($42.52) | Perf 3Y | 9.79% |
| Dividend Est. | $2.54 (4.13%) | EV/EBITDA | 8.31 | EPS Y/Y TTM | 83.17% | Gross Margin | 66.64% | Volatility(W/M) | 2.86% 2.91% | Perf 5Y | 6.74% |
| Dividend TTM | 2.52 | EV/Sales | 3.24 | Sales Y/Y TTM | 3.13% | Oper. Margin | 32.35% | ATR (14) | 1.84 | Perf 10Y | 22.91% |
| Dividend Ex-Date | 2026/10/2 | Quick Ratio | 1.38 | EPS Q/Q | 49.96% | Profit Margin | 18.87% | RSI (14) | 51.05 | Recom | 2.48 |
| Dividend Gr. 3/5Y | 4.37% 6.24% | Current Ratio | 1.53 | Sales Q/Q | 6.22% | SMA20 | 1.75% ($60.42) | Beta | 0.2 | Target Price | $65.3 |
| Payout | 71.98% | Debt/Eq | 2.02 | Earnings | 2026/10/29 | SMA50 | -2.72% ($63.2) | Rel Volume | 0.83 | Prev Close | $63 |
| Employees | 32500 | LT Debt/Eq | 1.96 | EPS/Sales Surpr. | 27.73% 10.51% | SMA200 | 2.79% ($59.81) | Avg Volume(3M) | 11.76M | Price | $61.48 |
| IPO | 1929/7/5 | Option/Short | Yes/Yes | Trades | 53319 | Volume | 9,763,149 | Change | -2.41% |
💊 A global large-cap pharmaceutical company with a broad new drug portfolio spanning oncology, immunology, cardiovascular, and hematology disease areas. The company in its current form was established through the 1989 merger of Bristol Myers and Squibb, is headquartered in New Jersey, and operates key blockbuster new drugs in the oncology and immunology fields.
Over the past 1 year, roughly in the middle
10% below its 1-year high.
Traded about as much as usual. That is 83% of its average volume.
Next earnings report: October 29
3 days to go.
BMY makes money exceptionally well
Of every $100 in sales, $32.35 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +3.0% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company expected to earn $100 next year, you would pay $929. Peers typically go for $1,515. Compared with its own 4-year average, it is 25% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +6.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
Dividends are paid consistently
Pays 4.13% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 85.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #11 of 21 in the industry
Based on market cap of $126B.
PFE#9 Pfizer Inc $171B PER 39.8 
NVO#10 Novo Nordisk ADR $131B PER 9.5 
BMY#11 Bristol-Myers Squibb Co $126B PER 13.5 
GSK#12 GSK Plc ADR $102B PER 16.0 
SNY#13 Sanofi ADR $99B PER 21.4 
Earnings Analysis · 7/30 Bristol-Myers Squibb ($BMY) Q2 2026 Earnings Analysis — Adjusted EPS and Revenue Beat by Wide Margins, Full-Year Guidance Raised Investing Guides · 4/11 2026 U.S. High-Dividend Stock Guide — How to Screen Out the Traps Investing Guides · 4/1 US Stock Taxes Complete Guide 2026 — Calculation Methods and Tax-Saving Strategies for Beginners See all posts on this stock FAQ
What kind of company is BMY?
BMY belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of BMY?
The market cap of BMY is approximately $125.6B, ranking 126 within its sector.
Does BMY pay dividends?
BMY has a dividend yield of approximately 4.13%, with an annual dividend of $2.54.
What is the P/E ratio of BMY?
BMY has a P/E ratio of approximately 13.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BMY?
BMY has recorded a 52-week high of $68.64 and a low of $42.52.
